the Evaluation of the Efficacy of TCI66207 on the Skin.
NCT ID: NCT05143034
Last Updated: 2021-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2018-11-01
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TCI66207 Essence
Essence
TCI66207 Essence
Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
Placebo Essence
Placebo Essence
Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TCI66207 Essence
Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
Placebo Essence
Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has dull skin.
Exclusion Criteria
2. Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.
3. Female who is pregnant or nursing or planning to become pregnant during the course of the study.
4. Received facial laser therapy, chemical peeling or UV overexposure in the past 4 weeks.
5. Subjects who have large spots (area \>3 square centimeter) or abnormal acne.
20 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TCI Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chia-Hua Liang, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Chia Nan University of Pharmacy ＆ Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research & Design Center, TCI CO., Ltd
Taipei, Neipu Township, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TSMH No.18-148-A
Identifier Type: -
Identifier Source: org_study_id